NFKB1 and cancer: Our findings and the reported regulation of RIPK1 activity suggest a model in which TAK1 exerts its pro-survival role in immune signaling activated GSCs as a negative regulator of RIPK1 activity rather than through activation of a pro-survival NF-κB transcriptional program as has been suggested previously in GSCs and other cancers [38, 39].